Pilocarpine drops did not clearly beat placebo for dry mouth in frailty

Design

Double-blind, placebo-controlled randomised trial, four weeks

Population

92 adults with xerostomia and a life-limiting condition or frailty

Primary outcome

Change in xerostomia severity at four weeks

Effect

No significant between-group difference; within-group improvement and better oral quality of life with pilocarpine

Xerostomia is common and distressing in frailty and at the end of life, and options are limited. This double-blind trial randomised 92 adults with troublesome dry mouth and a life-limiting condition or frailty to four weeks of topical pilocarpine drops or placebo.

There was no significant between-group difference in xerostomia severity at two or four weeks. Both arms improved early; only the pilocarpine group continued to improve between weeks two and four, and oral-health-related quality of life was better with pilocarpine at two weeks. Side effects were limited. Crucially, the trial enrolled 92 of the 120 participants its power calculation required, so it was underpowered to detect a modest effect.

The honest reading is that pilocarpine drops are not proven for this indication, though they were well tolerated and showed hints of benefit. Non-drug measures — frequent sips, saliva substitutes, oral hygiene and reviewing xerogenic medicines — remain the mainstay while better-powered trials are awaited.

• Double-blind trial, 92 adults with dry mouth and frailty or a life-limiting condition.
• No significant between-group difference in xerostomia severity at two or four weeks.
• Only pilocarpine continued to improve between weeks two and four, with better oral quality of life at two weeks.
• The trial was underpowered (92 of 120 needed) and pilocarpine was well tolerated.
• Keep non-drug measures and review of xerogenic medicines as the mainstay.

Why it matters

It tempers enthusiasm for a drug treatment of a common palliative symptom, keeping simple measures central.

Don't overread it

Underpowered, so a true modest benefit cannot be excluded; this does not establish that pilocarpine is ineffective.

The statistics, in plain English

A non-significant difference in an underpowered trial means absence of proof, not proof of no effect; the within-group improvements and quality-of-life signal leave the question genuinely open.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.